Mayo Clinic scientists propose a breast cancer drug for bladder cancer patients Oct. 08, 2014 Overview Show transcript Overview Researchers at Mayo Clinic have found amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors. These findings suggest that administering trastuzumab to MPUC patients with HER2 amplification could improve outcomes, just as it has for breast cancer. The study is published in Modern Pathology. Share Doximity Facebook LinkedIn Twitter Print details Receive Mayo Clinic news in your inbox. Sign up Related ContentVideoMayo Clinic Researchers Help to Shine New Light on Bladder Cancer TumorsArticleNew research indicates maintenance bacillus Calmette-Guerin is not cost-effective for all patients with intermediate- and high-risk nonmuscle invasive bladder cancerVideoBladder cancer discoveries implemented in multidisciplinary teams VID-20450111 Medical Professionals Mayo Clinic Scientists Propose a Breast Cancer Drug for Bladder Cancer Patients